RS62430B1 - Tienopiridini i benzotiofeni korisni kao irak4 inhibitori - Google Patents
Tienopiridini i benzotiofeni korisni kao irak4 inhibitoriInfo
- Publication number
- RS62430B1 RS62430B1 RS20211247A RSP20211247A RS62430B1 RS 62430 B1 RS62430 B1 RS 62430B1 RS 20211247 A RS20211247 A RS 20211247A RS P20211247 A RSP20211247 A RS P20211247A RS 62430 B1 RS62430 B1 RS 62430B1
- Authority
- RS
- Serbia
- Prior art keywords
- thienopyridines
- benzothiophenes
- useful
- irak4 inhibitors
- irak4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| EP18727589.6A EP3621960B1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62430B1 true RS62430B1 (sr) | 2021-11-30 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211247A RS62430B1 (sr) | 2017-05-11 | 2018-05-10 | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (sr) |
| EP (1) | EP3621960B1 (sr) |
| JP (1) | JP7154229B2 (sr) |
| KR (1) | KR102604900B1 (sr) |
| CN (1) | CN110612298B (sr) |
| AR (1) | AR111689A1 (sr) |
| AU (1) | AU2018265130B2 (sr) |
| BR (1) | BR112019023290A2 (sr) |
| CA (1) | CA3062602A1 (sr) |
| CL (1) | CL2019003198A1 (sr) |
| CO (1) | CO2019012494A2 (sr) |
| CY (1) | CY1124552T1 (sr) |
| DK (1) | DK3621960T3 (sr) |
| EA (1) | EA039189B1 (sr) |
| ES (1) | ES2889926T3 (sr) |
| HR (1) | HRP20211583T1 (sr) |
| HU (1) | HUE056493T2 (sr) |
| IL (1) | IL270494B (sr) |
| LT (1) | LT3621960T (sr) |
| MX (1) | MX2019012929A (sr) |
| PE (1) | PE20191817A1 (sr) |
| PL (1) | PL3621960T3 (sr) |
| PT (1) | PT3621960T (sr) |
| RS (1) | RS62430B1 (sr) |
| SI (1) | SI3621960T1 (sr) |
| TW (1) | TW201900640A (sr) |
| WO (1) | WO2018209012A1 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| MX2021006154A (es) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| WO2021016289A1 (en) * | 2019-07-23 | 2021-01-28 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| TW202309030A (zh) | 2021-05-07 | 2023-03-01 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
| AU2023214044A1 (en) | 2022-01-31 | 2024-08-08 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| ATE432929T1 (de) | 2001-06-15 | 2009-06-15 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| MX2007010973A (es) | 2005-03-09 | 2007-09-19 | Schering Corp | Compuestos para inhibir la actividad de cinesina de ksp. |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| CN101679376A (zh) | 2007-06-08 | 2010-03-24 | 拜尔农科股份有限公司 | 杀真菌剂杂环-嘧啶基-氨基衍生物 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| WO2010058846A1 (ja) | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| US8575153B2 (en) | 2008-11-28 | 2013-11-05 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| CA2772625A1 (en) | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011053701A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| JP2014515029A (ja) | 2011-04-29 | 2014-06-26 | アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ | キナーゼ阻害剤 |
| US9242975B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106641A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| AU2013341185B2 (en) | 2012-11-08 | 2017-07-13 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses |
| EP2922840B1 (en) | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| CU24406B1 (es) | 2014-04-04 | 2019-05-03 | Pfizer | 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida |
| EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| US10040802B2 (en) * | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10294229B2 (en) | 2015-06-24 | 2019-05-21 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| CA2996389C (en) | 2015-08-27 | 2020-04-07 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators |
-
2018
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active IP Right Grant
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en unknown
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
-
2019
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124552T1 (el) | 2022-07-22 |
| HRP20211583T1 (hr) | 2022-01-07 |
| ES2889926T3 (es) | 2022-01-14 |
| EP3621960A1 (en) | 2020-03-18 |
| EP3621960B1 (en) | 2021-08-04 |
| TW201900640A (zh) | 2019-01-01 |
| IL270494B (en) | 2022-04-01 |
| JP2020519596A (ja) | 2020-07-02 |
| CN110612298B (zh) | 2023-05-05 |
| EA201992674A1 (ru) | 2020-04-06 |
| MX2019012929A (es) | 2020-01-14 |
| AU2018265130A1 (en) | 2020-01-02 |
| WO2018209012A1 (en) | 2018-11-15 |
| CN110612298A (zh) | 2019-12-24 |
| AU2018265130B2 (en) | 2022-03-24 |
| PE20191817A1 (es) | 2019-12-27 |
| KR102604900B1 (ko) | 2023-11-21 |
| PT3621960T (pt) | 2021-09-16 |
| KR20200004871A (ko) | 2020-01-14 |
| SI3621960T1 (sl) | 2021-11-30 |
| LT3621960T (lt) | 2021-10-11 |
| EA039189B1 (ru) | 2021-12-15 |
| US10829496B2 (en) | 2020-11-10 |
| CL2019003198A1 (es) | 2020-03-20 |
| AR111689A1 (es) | 2019-08-07 |
| JP7154229B2 (ja) | 2022-10-17 |
| DK3621960T3 (da) | 2021-09-27 |
| HUE056493T2 (hu) | 2022-02-28 |
| CO2019012494A2 (es) | 2020-01-17 |
| PL3621960T3 (pl) | 2021-11-08 |
| BR112019023290A2 (pt) | 2020-06-16 |
| US20200062777A1 (en) | 2020-02-27 |
| CA3062602A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270494B (en) | Thienopyridines and benzothiophenase are useful as irak4 inhibitors | |
| PL3718370T3 (pl) | Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity | |
| IL269196A (en) | New inhibitors | |
| EP3268003A4 (en) | Thienopyrazine inhibitors of irak4 activity | |
| IL269711A (en) | ASK1 inhibitory compounds and their uses | |
| SG11202003790PA (en) | Composition and method | |
| EP3336091A4 (en) | IRAQ4 INHIBITOR AND ITS USE | |
| SI3621694T1 (sl) | Zaviralci lrrc33 in njihove uporabe | |
| IL263949A (en) | Complement inhibitors and their uses | |
| EP3336090A4 (en) | INHIBITOR OF IRAQ4 AND ITS USE | |
| IL274425A (en) | Pyrrolopyrazine derivatives as alpha five integrin inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| PT3725791T (pt) | Sal que serve como inibidor de akt e seu cristal | |
| IL275935A (en) | Its use and its derivative | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| EP3704104A4 (en) | IRAK4 INHIBITORS AND THEIR USES | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL281216A (en) | Inhibitors of glutaminyl cyclase | |
| ZA201904187B (en) | Method and composition | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201714238D0 (en) | Composition and method |